These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28895059)

  • 1. Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
    Stauch KL; Emanuel K; Lamberty BG; Morsey B; Fox HS
    J Neurovirol; 2017 Dec; 23(6):795-807. PubMed ID: 28895059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.
    Sanchez AB; Varano GP; de Rozieres CM; Maung R; Catalan IC; Dowling CC; Sejbuk NE; Hoefer MM; Kaul M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):168-79. PubMed ID: 26482305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz.
    Funes HA; Apostolova N; Alegre F; Blas-Garcia A; Alvarez A; Marti-Cabrera M; Esplugues JV
    J Infect Dis; 2014 Nov; 210(9):1385-95. PubMed ID: 24813473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.
    Blas-García A; Polo M; Alegre F; Funes HA; Martínez E; Apostolova N; Esplugues JV
    J Antimicrob Chemother; 2014 Nov; 69(11):2995-3000. PubMed ID: 25011651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals.
    Ciavatta VT; Bichler EK; Speigel IA; Elder CC; Teng SL; Tyor WR; García PS
    Neurochem Res; 2017 Nov; 42(11):3220-3232. PubMed ID: 28770436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo 2-deoxyglucose administration preserves glucose and glutamate transport and mitochondrial function in cortical synaptic terminals after exposure to amyloid beta-peptide and iron: evidence for a stress response.
    Guo ZH; Mattson MP
    Exp Neurol; 2000 Nov; 166(1):173-9. PubMed ID: 11031093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
    Sierra-Madero J; Di Perri G; Wood R; Saag M; Frank I; Craig C; Burnside R; McCracken J; Pontani D; Goodrich J; Heera J; Mayer H
    HIV Clin Trials; 2010; 11(3):125-32. PubMed ID: 20736149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Differences between Synaptic Mitochondria from the Striatum and the Cerebral Cortex.
    Petersen MH; Willert CW; Andersen JV; Waagepetersen HS; Skotte NH; Nørremølle A
    Neuroscience; 2019 May; 406():432-443. PubMed ID: 30876983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal ablation of GABAergic neurons prevents the in vivo neuroprotective effect of DCG-IV against the MPP+-induced neurotoxicity on dopaminergic nerve terminals.
    Venero JL; Mauriño R; Machado A; Santiago M
    Neurochem Int; 2010 Dec; 57(8):979-84. PubMed ID: 20974202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines.
    Funes HA; Blas-Garcia A; Esplugues JV; Apostolova N
    J Antimicrob Chemother; 2015 Aug; 70(8):2249-54. PubMed ID: 25925594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired spare respiratory capacity in cortical synaptosomes from Sod2 null mice.
    Flynn JM; Choi SW; Day NU; Gerencser AA; Hubbard A; Melov S
    Free Radic Biol Med; 2011 Apr; 50(7):866-73. PubMed ID: 21215798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    Lazzaro A; Vai D; Barco A; Stroffolini G; Pirriatore V; Guastamacchia G; Nigra M; Ghisetti V; Tettoni MC; Noce G; Giaccone C; Trunfio M; Trentalange A; Bonora S; Di Perri G; Calcagno A
    J Acquir Immune Defic Syndr; 2024 Oct; 97(2):180-191. PubMed ID: 39250652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The maraviroc expanded access program - safety and efficacy data from an open-label study.
    Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
    HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 6-hydroxydopamine on oxidative phosphorylation of mitochondria from rat striatum, cortex, and liver.
    Thakar JH; Hassan MN
    Can J Physiol Pharmacol; 1988 Apr; 66(4):376-9. PubMed ID: 3139267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
    McGee KC; Shahmanesh M; Boothby M; Nightingale P; Gathercole LL; Tripathi G; Harte AL; Shojaee-Moradie F; Umpleby AM; Das S; Al-Daghri NM; McTernan PG; Tomlinson JW
    Antivir Ther; 2012; 17(3):495-507. PubMed ID: 22300946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.
    Galindo J; Amariles P; Mueses-Marín HF; Hincapié JA; González-Avendaño S; Galindo-Orrego X
    BMC Infect Dis; 2016 Oct; 16(1):532. PubMed ID: 27716093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.